Literature DB >> 23526202

Hemorrhage after stereotactic biopsy from intra-axial brain lesions: incidence and avoidance.

Ahmed Abdel Sallam Shakal1, Esam Abdel Hay Mokbel1.   

Abstract

BACKGROUND: With the introduction of stereotactic surgery in humans by Spiegel and Wycis in 1947 and the great advances in neuroimaging, image-guided stereotactic brain biopsy is the mainstay for diagnosis of intrinsic deep-seated brain lesions. Stereotactic biopsy is usually safe, and the reported rate of complications is minimal, with mortality being reported in less than 1% and significant morbidity occurring in less than 5%. The complication most often encountered after stereotactic biopsy is hemorrhage. PATIENTS AND METHODS: A total of 150 patients (84 male and 66 female) with the mean age of 52.8 years having intra-axial brain lesions were included in the study. Image-guided (114 computed tomography [CT] and 36 magnetic resonance imaging [MRI]) stereotactic biopsy were performed by a specialized stereotactic neurosurgeon. Routine preoperative coagulation studies were performed in all patients. A workstation with multiplanar trajectory planning software was used. Serial biopsies were done with Sedan-type side cutting needle. Any detectable bleeding was analyzed by CT within 4 hours after procedure. All medical charts, laboratory results, preoperative imaging studies, and postoperative imaging studies were reviewed.
RESULTS: A conclusive histopathological diagnosis was achieved in 147 patients (98%). In 7 patients (4.7%), hemorrhage was detected in post-biopsy CT scan (3.3% asymptomatic and 1.4% symptomatic). Hemorrhage occurred in patients with highly malignant tumors. There was no mortality.
CONCLUSION: Using multiplanar image-guided trajectory planning and a small biopsy needle decreases the incidence of post-biopsy hemorrhage. Neurologically intact patients with no hemorrhage in post-biopsy CT scan could safely be discharged home at the same operative day. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2013        PMID: 23526202     DOI: 10.1055/s-0032-1325633

Source DB:  PubMed          Journal:  J Neurol Surg A Cent Eur Neurosurg        ISSN: 2193-6315            Impact factor:   1.268


  6 in total

1.  Perfusion and diffusion-weighted imaging parameters: Comparison between pre- and postbiopsy MRI for high-grade glioma.

Authors:  Ryo Kurokawa; Akira Baba; Mariko Kurokawa; Aristides Capizzano; Yoshiaki Ota; John Kim; Ashok Srinivasan; Toshio Moritani
Journal:  Medicine (Baltimore)       Date:  2022-09-02       Impact factor: 1.817

2.  Outpatient stereotactic brain biopsies.

Authors:  Bertrand Mathon; Pauline Marijon; Maximilien Riche; Vincent Degos; Alexandre Carpentier
Journal:  Neurosurg Rev       Date:  2021-06-23       Impact factor: 2.800

3.  Residual Tumor Volume as Best Outcome Predictor in Low Grade Glioma - A Nine-Years Near-Randomized Survey of Surgery vs. Biopsy.

Authors:  Roland Roelz; David Strohmaier; Ramazan Jabbarli; Rainer Kraeutle; Karl Egger; Volker A Coenen; Astrid Weyerbrock; Peter C Reinacher
Journal:  Sci Rep       Date:  2016-08-30       Impact factor: 4.379

4.  Comparison of Stereotactic and Ultrasound-guided Biopsy of Solid Supratentorial Tumor: A Preliminary Report.

Authors:  Guru Dutta Satyarthee; P Sarat Chandra; Bhawani S Sharma; V S Mehta
Journal:  Asian J Neurosurg       Date:  2017 Oct-Dec

5.  Application of stereotactic biopsy for diagnosing intracranial lesions in patients with AIDS in China: Report of 7 cases.

Authors:  Ji-Bo Zhang; Kai Fu; Rui Gong; Xue-Meng Liu; Li-Dao Chen; Yong-Xi Zhang; Gui-Fang Yang; Jie Zhang
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.817

6.  Frame-based stereotactic biopsies using an intraoperative MR-scanner are as safe and effective as conventional stereotactic procedures.

Authors:  Jan-Oliver Neumann; Benito Campos; Bilal Younes; Martin Jakobs; Christine Jungk; Christopher Beynon; Andreas von Deimling; Andreas Unterberg; Karl Kiening
Journal:  PLoS One       Date:  2018-10-23       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.